For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...

Genentech’s newly approved multiple sclerosis (MS) injection takes about 10 minutes to administer, dramatically reducing the ...

When Roche's Genentech gained approval for Ocrevus in 2017, the first-in- | On the same day that Roche gained an FDA approval ...

An AstraZeneca immunotherapy improved survival rates in patients with bladder cancer, results that could reshape treatment of ...

Gilead Sciences to pay $35 million upfront in AI drug discovery deal with Stanford University spinout backed by Nvidia and ...

Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults.

The US Food and Drug Administration (FDA) has approved Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and ...

Tecentriq Hybreza can be administered over seven minutes, compared with 30 to 60 minutes for IV infusion of Tecentriq. There ...

Ocrevus Zunovo can be administrated by providers twice a year with a 10-minute subcutaneous injection. Ocrevus Zunovo will be ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...

The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...